701 related articles for article (PubMed ID: 16678649)
21. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response.
Newcorn JH; Kratochvil CJ; Allen AJ; Casat CD; Ruff DD; Moore RJ; Michelson D;
Am J Psychiatry; 2008 Jun; 165(6):721-30. PubMed ID: 18281409
[TBL] [Abstract][Full Text] [Related]
22. A randomized, double-blind study of 30 versus 20 mg dexmethylphenidate extended-release in children with attention-deficit/hyperactivity disorder: late-day symptom control.
Brams M; Turnbow J; Pestreich L; Giblin J; Childress A; McCague K; Muniz R
J Clin Psychopharmacol; 2012 Oct; 32(5):637-44. PubMed ID: 22926597
[TBL] [Abstract][Full Text] [Related]
23. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes.
Faraone SV; Glatt SJ
J Clin Psychiatry; 2010 Jun; 71(6):754-63. PubMed ID: 20051220
[TBL] [Abstract][Full Text] [Related]
24. Atomoxetine. Attention-deficit/hyperactivity disorder: no better than methylphenidate.
Prescrire Int; 2010 Feb; 19(105):5-8. PubMed ID: 20455329
[TBL] [Abstract][Full Text] [Related]
25. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
Medori R; Ramos-Quiroga JA; Casas M; Kooij JJ; Niemelä A; Trott GE; Lee E; Buitelaar JK
Biol Psychiatry; 2008 May; 63(10):981-9. PubMed ID: 18206857
[TBL] [Abstract][Full Text] [Related]
26. Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study.
Adler LA; Spencer TJ; Williams DW; Moore RJ; Michelson D
J Atten Disord; 2008 Nov; 12(3):248-53. PubMed ID: 18448861
[TBL] [Abstract][Full Text] [Related]
27. Does atomoxetine improve executive function, inhibitory control, and hyperactivity? Results from a placebo-controlled trial using quantitative measurement technology.
Wehmeier PM; Schacht A; Ulberstad F; Lehmann M; Schneider-Fresenius C; Lehmkuhl G; Dittmann RW; Banaschewski T
J Clin Psychopharmacol; 2012 Oct; 32(5):653-60. PubMed ID: 22926599
[TBL] [Abstract][Full Text] [Related]
28. Atomoxetine for attention deficit hyperactivity disorder in mental retardation.
Fernández-Jaén A; Fernández-Mayoralas DM; Calleja Pérez B; Muñoz Jareño N; Campos Díaz Mdel R
Pediatr Neurol; 2010 Nov; 43(5):341-7. PubMed ID: 20933178
[TBL] [Abstract][Full Text] [Related]
29. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial.
Sallee FR; McGough J; Wigal T; Donahue J; Lyne A; Biederman J;
J Am Acad Child Adolesc Psychiatry; 2009 Feb; 48(2):155-65. PubMed ID: 19106767
[TBL] [Abstract][Full Text] [Related]
30. A randomized, double-blind and placebo-controlled trial of modafinil in children and adolescents with attention deficit and hyperactivity disorder.
Kahbazi M; Ghoreishi A; Rahiminejad F; Mohammadi MR; Kamalipour A; Akhondzadeh S
Psychiatry Res; 2009 Aug; 168(3):234-7. PubMed ID: 19439364
[TBL] [Abstract][Full Text] [Related]
31. Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder.
Weisler RH; Pandina GJ; Daly EJ; Cooper K; Gassmann-Mayer C;
CNS Drugs; 2012 May; 26(5):421-34. PubMed ID: 22519922
[TBL] [Abstract][Full Text] [Related]
32. Does placebo response differ between objective and subjective measures in children with attention-deficit/hyperactivity disorder?
Sumner CR; Haynes VS; Teicher MH; Newcorn JH
Postgrad Med; 2010 Sep; 122(5):52-61. PubMed ID: 20861588
[TBL] [Abstract][Full Text] [Related]
33. Double-blind, placebo-controlled study of zinc sulfate in the treatment of attention deficit hyperactivity disorder.
Bilici M; Yildirim F; Kandil S; Bekaroğlu M; Yildirmiş S; Değer O; Ulgen M; Yildiran A; Aksu H
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):181-90. PubMed ID: 14687872
[TBL] [Abstract][Full Text] [Related]
34. Modafinil improves symptoms of attention-deficit/hyperactivity disorder across subtypes in children and adolescents.
Biederman J; Pliszka SR
J Pediatr; 2008 Mar; 152(3):394-9. PubMed ID: 18280848
[TBL] [Abstract][Full Text] [Related]
35. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.
Durell TM; Adler LA; Williams DW; Deldar A; McGough JJ; Glaser PE; Rubin RL; Pigott TA; Sarkis EH; Fox BK
J Clin Psychopharmacol; 2013 Feb; 33(1):45-54. PubMed ID: 23277268
[TBL] [Abstract][Full Text] [Related]
36. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial.
Kratochvil CJ; Heiligenstein JH; Dittmann R; Spencer TJ; Biederman J; Wernicke J; Newcorn JH; Casat C; Milton D; Michelson D
J Am Acad Child Adolesc Psychiatry; 2002 Jul; 41(7):776-84. PubMed ID: 12108801
[TBL] [Abstract][Full Text] [Related]
37. Improvements in executive function correlate with enhanced performance and functioning and health-related quality of life: evidence from 2 large, double-blind, randomized, placebo-controlled trials in ADHD.
Brown TE; Landgraf JM
Postgrad Med; 2010 Sep; 122(5):42-51. PubMed ID: 20861587
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population.
Christensen L; Sasané R; Hodgkins P; Harley C; Tetali S
Curr Med Res Opin; 2010 Apr; 26(4):977-89. PubMed ID: 20178404
[TBL] [Abstract][Full Text] [Related]
39. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
Dittmann RW; Schacht A; Helsberg K; Schneider-Fresenius C; Lehmann M; Lehmkuhl G; Wehmeier PM
J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):97-110. PubMed ID: 21488751
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naïve children and adolescents with attention deficit/hyperactivity disorder.
Montoya A; Hervas A; Cardo E; Artigas J; Mardomingo MJ; Alda JA; Gastaminza X; García-Polavieja MJ; Gilaberte I; Escobar R
Curr Med Res Opin; 2009 Nov; 25(11):2745-54. PubMed ID: 19785510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
